Next Article in Journal
Monitoring of Physiological Parameters to Predict Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review
Next Article in Special Issue
Mechanisms of Regulatory B cell Function in Autoimmune and Inflammatory Diseases beyond IL-10
Previous Article in Journal
Case Formulation in Young People with Post-Traumatic Stress Disorder and First-Episode Psychosis
Previous Article in Special Issue
B Cell Receptor Affinity for Insulin Dictates Autoantigen Acquisition and B Cell Functionality in Autoimmune Diabetes
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2016, 5(12), 107; doi:10.3390/jcm5120107

Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies

Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
Department of Project Management, MedImmune, Gaithersburg, MD 20878, USA
Department of Oncology Research, MedImmune, Gaithersburg, MD 20878, USA
Author to whom correspondence should be addressed.
Academic Editor: Bonnie N. Dittel
Received: 2 October 2016 / Revised: 14 November 2016 / Accepted: 17 November 2016 / Published: 24 November 2016
(This article belongs to the Special Issue B Cells in Autoimmunity)
View Full-Text   |   Download PDF [222 KB, uploaded 24 November 2016]


Exaggerated or inappropriate responses by B cells are an important feature in many types of autoimmune neurological diseases. The recent success of B-cell depletion in the treatment of multiple sclerosis (MS) has stimulated the development of novel B-cell-targeting therapies with the potential for improved efficacy. CD19 has emerged as a promising target for the depletion of B cells as well as CD19-positive plasmablasts and plasma cells. Inebilizumab (MEDI-551), an anti-CD19 antibody with enhanced antibody-dependent cell-mediated cytotoxicity against B cells, is currently being evaluated in MS and neuromyelitis optica. This review discusses the role of B cells in autoimmune neurological disorders, summarizes the development of inebilizumab, and analyzes the recent results for inebilizumab treatment in an autoimmune encephalitis mouse model. The novel insights obtained from these preclinical studies can potentially guide future investigation of inebilizumab in patients. View Full-Text
Keywords: CD19; B-cell depletion; autoimmunity; multiple sclerosis; neuromyelitis optica CD19; B-cell depletion; autoimmunity; multiple sclerosis; neuromyelitis optica
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Chen, D.; Gallagher, S.; Monson, N.L.; Herbst, R.; Wang, Y. Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. J. Clin. Med. 2016, 5, 107.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top